GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » Cash Flow from Discontinued Operations

Clover Biopharmaceuticals (HKSE:02197) Cash Flow from Discontinued Operations : HK$0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Clover Biopharmaceuticals's cash flow from discontinued operations for the six months ended in Jun. 2024 was HK$0.00 Mil. It means Clover Biopharmaceuticals received HK$0.00 Mil from the sale of part of business quarterly. Clover Biopharmaceuticals's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.00 Mil.


Clover Biopharmaceuticals Cash Flow from Discontinued Operations Historical Data

The historical data trend for Clover Biopharmaceuticals's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Biopharmaceuticals Cash Flow from Discontinued Operations Chart

Clover Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Discontinued Operations
- - - - -

Clover Biopharmaceuticals Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Discontinued Operations Get a 7-Day Free Trial Premium Member Only - - - - -

Clover Biopharmaceuticals Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clover Biopharmaceuticals Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Clover Biopharmaceuticals's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Clover Biopharmaceuticals Business Description

Industry
Traded in Other Exchanges
N/A
Address
No. 758 West Nanjing Road, Room 1901, Jing’an District, Shanghai, CHN
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.
Executives
Liang Peng 2101 Beneficial owner
Liang Joshua G 2501 Other
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Aut-xxi Investment Holdings Limited 2201 Interest of corporation controlled by you
Jnry V Holdings Limited 2101 Beneficial owner
Aut-xxi Hk Holdings Limited 2101 Beneficial owner
Aut-xxi Holdings Limited 2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Super Novel International Limited 2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals Headlines

No Headlines